The GLP-1 receptor agonist NLY01 delayed onset and reduced severity of experimental multiple sclerosis by suppressing inflammation, blocking immune cell trafficking into the brain, and preventing neuron loss.
Dual anti-inflammatory + neuroprotectiveNLY01 both suppresses the immune attack on myelin AND directly protects neurons from death — addressing the unmet need in MS treatment
What the researchers found
NLY01 delayed EAE onset and reduced severity in prevention paradigm, inhibited immune cell activation and CNS trafficking, suppressed chemokine production, blocked neurotoxic astrocyte genes, prevented retinal ganglion cell loss, and reduced clinical scores in relapsing-remitting EAE.
Why it matters
MS currently has no approved neuroprotective therapy. GLP-1 drugs that both suppress inflammation and protect neurons could fundamentally change MS treatment by addressing the component that causes permanent disability.
The numbers in context
Delayed onset; reduced severity; suppressed splenic immune cells; reduced CNS trafficking; blocked neurotoxic astrocyte genes; prevented RGC loss; reduced relapse in RR-EAE
How the study worked
Preclinical study. Mouse experimental autoimmune encephalomyelitis (EAE) model. Prevention and therapeutic paradigms tested. Immune cell analysis, chemokine profiling, gene expression in optic nerves, and retinal ganglion cell quantification.
Who was studied
C57BL/6 mice with experimental autoimmune encephalomyelitis (EAE)
What this study cannot tell us
Mouse EAE model only — human MS is more complex. Prevention paradigm (pre-disease) is less clinically relevant than therapeutic paradigm. NLY01 has not been tested in MS patients. EAE models may not capture all aspects of progressive MS.
How to read the evidence
Moderate evidence: well-designed preclinical study with both prevention and therapeutic paradigms, but limited to mouse EAE models. NLY01 is in clinical development for another neurological condition (Parkinson's).
When this study was published
Published 2021. GLP-1 agonists for MS are being investigated further, with NLY01 in clinical development for neurological indications.
The bigger picture
GLP-1 drugs continue to reveal benefits across neurological conditions — from Parkinson's to now MS. Their combined anti-inflammatory and neuroprotective effects make them compelling candidates for neurodegenerative diseases where current treatments only address symptoms.
Questions still open
- Will NLY01 or other GLP-1 drugs be effective in human MS clinical trials?
- Could GLP-1 drugs help with progressive MS where current treatments fail?
- Would combining GLP-1 agonists with existing MS immunotherapies provide additive benefit?
Common questions
Could diabetes drugs like Ozempic help with multiple sclerosis?
How is this different from current MS treatments?
Read the original research
Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 18(3), 1834-1848
Citation
Gharagozloo, Marjan; Smith, Matthew D; Sotirchos, Elias S; Jin, Jing; Meyers, Keya; Taylor, Michelle; Garton, Thomas; Bannon, Riley; Lord, Hannah-Noelle; Dawson, Ted M; Dawson, Valina L; Lee, Seulki; Calabresi, Peter A. (2021). Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 18(3), 1834-1848. https://doi.org/10.1007/s13311-021-01088-5